Ann: Security Class Reinstatement to Quotation- OPTOB, page-556

  1. 1,665 Posts.
    lightbulb Created with Sketch. 340
    All things considered, I believe the multiple will be between 3 - 3.5 x peak sales. I estimate peak sales to be a minimum $1.6B per year. That's based on Sozinibercept priced at half of Eylea ( or equivalent). Pricing will be determined largely by others (reimbursement), and I 50% is the lowest estimate. Could be 60-70%.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.